悦康药业：关于自愿披露子公司注射用YKYY031获得国家药品监督管理局临床试验批准的公告

Core Viewpoint - Yuyuan Pharmaceutical announced that its wholly-owned subsidiary, Beijing Yuyuan Ketech Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have received approval from the National Medical Products Administration for the clinical trial of YKYY031 for advanced solid tumors [2] Group 1 - The approval pertains to the clinical trial of an injectable drug, YKYY031, specifically targeting advanced solid tumors [2] - The announcement was made on the evening of December 12 [2] - This development indicates progress in the company's research and development efforts in oncology [2]